Dementia Risk Prediction Model: Development and Validation

Development and Validation of a Multivariable Dementia Risk Prediction Model in UK Adults Using Routinely Available Predictors

At present, there is no treatment for dementia that changes the course of the disease. However, it is now understood that the proteins in dementias such as Alzheimer's disease are present years before someone develops symptoms of dementia. Studies may therefore need to give potential treatments to patients before they develop symptoms of dementia. To do this, researchers need a way of predicting who will go on to develop dementia in the future.

There are several ways of doing this, however, many of these methods are costly and difficult to implement at a population level - such as brain imaging, lumbar punctures or psychological tests. In this study, the investigators aim to develop a method of predicting who will go on to develop dementia (and dementia due to Alzheimer's disease) using only the sort of information that a general practitioner would have available to them.

To do this, the investigators will develop a dementia prediction model using data from the Secure Anonymised Information Linkage (SAIL) Databank, which contains anonymised primary care, hospital admissions and mortality data for the population of Wales, United Kingdom (UK). They will then go on to test how well it performs in an external dataset, such as the UK's Clinical Practice Research Datalink (CPRD).

Study Overview

• Status: Active, not recruiting
• Conditions: Dementia Alzheimers
• Intervention / Treatment: Other: This is not an intervention study

Detailed Description

To date, no dementia drugs have shown a disease-modifying effect in clinical trials. It is now understood that the pathology underlying Alzheimer's disease is present decades before symptoms become apparent. Starting an intervention only when a patient develops cognitive symptoms, and therefore when there is substantial disease burden, may reduce the chance of any disease-modifying effect. Instead, targeting interventions earlier, when the pathological burden is lower, may increase the likelihood of preventing or delaying dementia onset.

Consequently, there is a need for a method that identifies patients who are at an increased risk of developing dementia. This requires the development of a risk prediction model, which utilises multiple predictors in combination to produce individualised estimates of the risk of developing dementia risk over time.

An ideal risk prediction model for a population-based application would need to use predictors that are already available to, or readily obtainable by, general practitioners (GPs). Such a predictive tool could be used as a low cost, scalable method of recruiting an 'at risk' group of participants to future trials of risk modification strategies or preventative therapies. Once an effective disease-modifying intervention is identified, clinicians could use the same model to identify at-risk patients who may benefit most from undergoing the intervention.

An ideal dementia risk prediction tool would contain only information that is readily available to, or easily obtainable by, clinicians such as General Practitioners (GPs).

The investigators aim to develop two 10-year risk prediction models: one to predict all-cause dementia and one to predict Alzheimer's disease dementia, in UK adults aged 60-79 years, using only predictors that are routinely available to GPs. They will develop the model using data from the Secure Anonymised Information Linkage (SAIL) Databank, which is composed of anonymised, linked primary care, hospital admissions and mortality data for the population of Wales, UK.

The investigators will then go on to externally validate their dementia risk prediction models in an external dataset, such as the UK's Clinical Practice Research Datalink (CPRD). They will also validate an existing, published study using data from the The Health Improvement Network (THIN) (Walters et al. 2016) using this external dataset, allowing us to compare the performance of the models.

• Study Type: Observational
• Enrollment (Anticipated): 400000

Contacts and Locations

Study Locations

• United Kingdom
  • Midlothian
    • Edinburgh, Midlothian, United Kingdom
      • Usher Institute, University of Edinburgh

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years to 79 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

We will use data from the Secure Anonymised Information Linkage Databank Dementia electronic Cohort (SAIL-DeC). SAIL-DeC was created as a flexible, national electronic cohort ('e-cohort') to facilitate dementia research using routinely-collected healthcare data. SAIL participants were included in SAIL-DeC based on date of birth (1/1/1900 to 1/4/1958) and if linked primary care data were available (1.2 million individuals).

Description

Inclusion Criteria:

• Registered with a SAIL practice before 2008
• Aged between 60-79 during the study window (1st January 2008 to 31st December 2017)
• Aged 60-79 years by January 2008

Exclusion Criteria:

• Deprivation quintile missing for the start of follow-up (deprivation scores will probably not be missing at random)
• All-cause dementia code in any dataset prior to 1st January 2008 (i.e. dementia diagnosis at baseline)

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Population-based; Population-based cohort of participants registered with a SAIL-contributing practice.	Other: This is not an intervention study; This study is based on retrospective analysis of linked routinely-collected healthcare data

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dementia	Development of dementia during follow-up	10 years
Alzheimer's disease	Development of Alzheimer's disease dementia during follow-up	10 years

Collaborators and Investigators

• Sponsor: University of Edinburgh
• Collaborators: Keele University

Study record dates

Study Major Dates

• Study Start (Actual): May 8, 2019
• Primary Completion (Actual): May 8, 2019
• Study Completion (Anticipated): August 1, 2023

Study Registration Dates

• First Submitted: May 7, 2019
• First Submitted That Met QC Criteria: May 7, 2019
• First Posted (Actual): May 9, 2019

Study Record Updates

• Last Update Posted (Actual): November 3, 2022
• Last Update Submitted That Met QC Criteria: November 2, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Tauopathies; Dementia; Alzheimer Disease
• Other Study ID Numbers: AC19049

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Researchers can apply to the SAIL databank (saildatabank.com) to access the individual participant data.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No